Abstract
Since the isolation and identification of the retinoid X receptor (RXR) as a member of the nuclear receptor (NR) superfamily in 1990, its analysis has ushered in a new understanding of physiological regulation by nuclear receptors, and novel methods to identify other unknown and orphan receptors. Expression of one or more of the three isoforms of RXR—α, β, and γ—can be found in every human cell type. Biologically, RXR plays a critical role through its ability to partner with other nuclear receptors. RXR is able to regulate nutrient metabolism by forming “permissive” heterodimers with peroxisome proliferator-activated receptor (PPAR), liver-X-receptor (LXR), farnesoid X receptor (FXR), pregnane X receptor (PXR) and constitutive androstane receptor (CAR), which function when ligands are bound to one or both of the heterodimer partners. Conversely, RXR is able to form “nonpermissive” heterodimers with vitamin D receptor (VDR), thyroid receptor (TR) and retinoic acid receptor (RAR), which function only in the presence of vitamin D, T3 and retinoic acid, respectively. Furthermore, RXR can form homodimers in the presence of a selective agonist, or rexinoid, to regulate gene expression and to either inhibit proliferation or induce apoptosis in human cancers. Thus, over the last 25 years there have been several reports on the design and synthesis of small molecule rexinoids. This review summarizes the synthetic methods for several of the most potent rexinoids thus far reported.
Keywords: Ligand, Organic synthesis, Retinoid, Rexinoid, RXR.
Current Topics in Medicinal Chemistry
Title:Retinoid X Receptor Selective Agonists and their Synthetic Methods
Volume: 17 Issue: 6
Author(s): Carl E. Wagner, Peter W. Jurutka, Pamela A. Marshall and Michael C. Heck
Affiliation:
Keywords: Ligand, Organic synthesis, Retinoid, Rexinoid, RXR.
Abstract: Since the isolation and identification of the retinoid X receptor (RXR) as a member of the nuclear receptor (NR) superfamily in 1990, its analysis has ushered in a new understanding of physiological regulation by nuclear receptors, and novel methods to identify other unknown and orphan receptors. Expression of one or more of the three isoforms of RXR—α, β, and γ—can be found in every human cell type. Biologically, RXR plays a critical role through its ability to partner with other nuclear receptors. RXR is able to regulate nutrient metabolism by forming “permissive” heterodimers with peroxisome proliferator-activated receptor (PPAR), liver-X-receptor (LXR), farnesoid X receptor (FXR), pregnane X receptor (PXR) and constitutive androstane receptor (CAR), which function when ligands are bound to one or both of the heterodimer partners. Conversely, RXR is able to form “nonpermissive” heterodimers with vitamin D receptor (VDR), thyroid receptor (TR) and retinoic acid receptor (RAR), which function only in the presence of vitamin D, T3 and retinoic acid, respectively. Furthermore, RXR can form homodimers in the presence of a selective agonist, or rexinoid, to regulate gene expression and to either inhibit proliferation or induce apoptosis in human cancers. Thus, over the last 25 years there have been several reports on the design and synthesis of small molecule rexinoids. This review summarizes the synthetic methods for several of the most potent rexinoids thus far reported.
Export Options
About this article
Cite this article as:
Wagner E. Carl, Jurutka W. Peter, Marshall A. Pamela and Heck C. Michael, Retinoid X Receptor Selective Agonists and their Synthetic Methods, Current Topics in Medicinal Chemistry 2017; 17 (6) . https://dx.doi.org/10.2174/1568026616666160617091559
DOI https://dx.doi.org/10.2174/1568026616666160617091559 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Genes that Modulate the Sensitivity for Anti-Microtubule Drug-Mediated Chemotherapy
Current Cancer Drug Targets High CXCR4 Expression Correlates with Sunitinib Poor Response in Metastatic Renal Cancer
Current Cancer Drug Targets Anaemia, Polycythaemia and Chronic Heart Failure
Current Cardiology Reviews Ghrelin and Energy Balance: Focus on Current Controversies
Current Drug Targets Pharmaceutical Nanotechnology United States Patent Watch (January – March 2016)
Pharmaceutical Nanotechnology The Role of Therapeutic Drugs on Acquired Mitochondrial Toxicity
Current Drug Metabolism Oxidative Stress and Antioxidants in Carcinogenesis and Integrative Therapy of Cancer
Current Pharmaceutical Design Nitric Oxide Synthase and Cyclooxygenase Pathways: A Complex Interplay in Cellular Signaling
Current Medicinal Chemistry Oestrogen-A Protective Factor in Schizophrenia?
Current Psychiatry Reviews Withdrawal Notice: Drug Repurposing for Prospective Anti-Cancer Agents Along with the Clinical Status of the Repurposed Drug
Anti-Cancer Agents in Medicinal Chemistry Screening of Candidate Pathogenic Genes for Spontaneous Abortion Using Whole Exome Sequencing
Combinatorial Chemistry & High Throughput Screening Prader-Willi Syndrome: Clinical Genetics and Diagnostic Aspects with Treatment Approaches
Current Pediatric Reviews Rac-1 as a New Therapeutic Target in Cerebro- and Cardio-Vascular Diseases
Current Drug Targets Insulin-like Growth Factor: Current Concepts and New Developments in Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Molecular Modelling Studies on Thiazole-Based α-Glucosidase Inhibitors Using Docking and CoMFA, CoMSIA and HQSAR
Current Drug Discovery Technologies Current Perspectives on Anti-Aging Interventions
Letters in Drug Design & Discovery Recent Advances in the Development of Multi-Kinase Inhibitors
Mini-Reviews in Medicinal Chemistry Emerging Role of Apelin as a Therapeutic Target in Cancer: A Patent Review
Recent Patents on Anti-Cancer Drug Discovery C-11 Radiochemistry in Cancer Imaging Applications
Current Topics in Medicinal Chemistry New Molecules and Strategies in the Field of Anticancer Agents
Current Medicinal Chemistry - Anti-Cancer Agents